1. Home
  2. MC vs CYTK Comparison

MC vs CYTK Comparison

Compare MC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MC
  • CYTK
  • Stock Information
  • Founded
  • MC 2007
  • CYTK 1997
  • Country
  • MC United States
  • CYTK United States
  • Employees
  • MC N/A
  • CYTK N/A
  • Industry
  • MC Investment Managers
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • MC Finance
  • CYTK Health Care
  • Exchange
  • MC Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • MC 5.5B
  • CYTK 4.6B
  • IPO Year
  • MC 2014
  • CYTK 2004
  • Fundamental
  • Price
  • MC $75.35
  • CYTK $47.56
  • Analyst Decision
  • MC Hold
  • CYTK Buy
  • Analyst Count
  • MC 7
  • CYTK 15
  • Target Price
  • MC $69.67
  • CYTK $75.57
  • AVG Volume (30 Days)
  • MC 535.5K
  • CYTK 2.9M
  • Earning Date
  • MC 10-22-2025
  • CYTK 11-05-2025
  • Dividend Yield
  • MC 3.45%
  • CYTK N/A
  • EPS Growth
  • MC 1309.15
  • CYTK N/A
  • EPS
  • MC 2.67
  • CYTK N/A
  • Revenue
  • MC $1,384,443,000.00
  • CYTK $85,738,000.00
  • Revenue This Year
  • MC $24.90
  • CYTK $330.96
  • Revenue Next Year
  • MC $17.16
  • CYTK $73.41
  • P/E Ratio
  • MC $28.25
  • CYTK N/A
  • Revenue Growth
  • MC 42.85
  • CYTK 2635.74
  • 52 Week Low
  • MC $47.00
  • CYTK $29.31
  • 52 Week High
  • MC $82.89
  • CYTK $59.39
  • Technical
  • Relative Strength Index (RSI)
  • MC 61.00
  • CYTK 56.53
  • Support Level
  • MC $73.54
  • CYTK $49.22
  • Resistance Level
  • MC $76.34
  • CYTK $53.58
  • Average True Range (ATR)
  • MC 1.82
  • CYTK 2.73
  • MACD
  • MC 0.21
  • CYTK -0.07
  • Stochastic Oscillator
  • MC 74.31
  • CYTK 64.95

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: